Drugs / KN069
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06547775 | Aug 2024 → Apr 2027 expected | obesity disorder | Suzhou Alphamab Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN069 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06547775 ↗ |
| Route | Subcutaneous | “Participants will receive a single SC KN069 12mg.” NCT06547775 ↗ |
| Target | GIPR | “KN069, a novel dual Glucagon-like peptide-1 receptor agonist (GLP-1RA)/Glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist” PMID 42010360 ↗ Apr 2026 |